These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36257291)

  • 1. Predictive Value of the Hepatic Immune Predictive Index for Patients with Primary Liver Cancer Treated with Immune Checkpoint Inhibitors.
    Hong C; Dong HZ; Li RN; Zhu HB; Li QM; Cui H; Hu CY; Huang CY; Peng J; Liu L; Zou XJ; Xiao LS
    Dig Dis; 2023; 41(3):422-430. PubMed ID: 36257291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors.
    Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ
    BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies.
    Zhang L; Feng J; Kuang T; Chai D; Qiu Z; Deng W; Dong K; Zhao K; Wang W
    Int Immunopharmacol; 2023 May; 118():110019. PubMed ID: 36933492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: a systematic review with meta-analysis.
    Tian BW; Yan LJ; Ding ZN; Liu H; Meng GX; Xue JS; Han CL; Dong ZR; Hong JG; Chen ZQ; Wang DX; Li T
    Expert Rev Gastroenterol Hepatol; 2023 Jan; 17(1):73-83. PubMed ID: 36476076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti-PD-1 therapy.
    Dharmapuri S; Özbek U; Lin JY; Sung M; Schwartz M; Branch AD; Ang C
    Cancer Med; 2020 Jul; 9(14):4962-4970. PubMed ID: 32419290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma: a meta-analysis based on 40 cohorts incorporating 3697 individuals.
    Wang R; Lin N; Mao B; Wu Q
    J Cancer Res Clin Oncol; 2022 May; 148(5):1195-1210. PubMed ID: 34297207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma.
    Kim HI; Lim J; Shim JH
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):2069-2077. PubMed ID: 34459972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma.
    Shao YY; Liu TH; Hsu C; Lu LC; Shen YC; Lin ZZ; Cheng AL; Hsu CH
    Liver Int; 2019 Nov; 39(11):2184-2189. PubMed ID: 31400295
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-fetoprotein predicts the treatment efficacy of immune checkpoint inhibitors for gastric cancer patients.
    Zhang J; Wang L; Zhang S; Cao R; Zhao Y; Zhao Y; Song Y; Guo Z
    BMC Cancer; 2024 Feb; 24(1):266. PubMed ID: 38408930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors.
    Xu S; Lai R; Zhao Q; Zhao P; Zhao R; Guo Z
    Front Immunol; 2021; 12():794099. PubMed ID: 34950153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefits of combination therapy with immune checkpoint inhibitors and predictive role of tumour mutation burden in hepatocellular carcinoma: A systematic review and meta-analysis.
    Zheng J; Shao M; Yang W; Ren J; Chen X; Yang H
    Int Immunopharmacol; 2022 Nov; 112():109244. PubMed ID: 36126410
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An elevated neutrophil-to-lymphocyte ratio predicts a poor postoperative survival in primary hepatocellular carcinoma patients with a normal preoperative serum level of alpha-fetoprotein.
    Shiraki T; Ishizuka M; Kubota K; Kato M; Matsumoto T; Mori S; Shimizu T; Aoki T
    Surg Today; 2019 Aug; 49(8):661-669. PubMed ID: 30806789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
    Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
    Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reductions in AFP and PIVKA-II can predict the efficiency of anti-PD-1 immunotherapy in HCC patients.
    Sun X; Mei J; Lin W; Yang Z; Peng W; Chen J; Zhang Y; Xu L; Chen M
    BMC Cancer; 2021 Jul; 21(1):775. PubMed ID: 34218801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serine Protease Inhibitor Kazal Type 1, A Potential Biomarker for the Early Detection, Targeting, and Prediction of Response to Immune Checkpoint Blockade Therapies in Hepatocellular Carcinoma.
    Jia J; Ga L; Liu Y; Yang Z; Wang Y; Guo X; Ma R; Liu R; Li T; Tang Z; Wang J
    Front Immunol; 2022; 13():923031. PubMed ID: 35924241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blood neutrophil-lymphocyte ratio predicts survival after hepatectomy for hepatocellular carcinoma: A propensity score-based analysis.
    Yang HJ; Guo Z; Yang YT; Jiang JH; Qi YP; Li JJ; Li LQ; Xiang BD
    World J Gastroenterol; 2016 Jun; 22(21):5088-95. PubMed ID: 27275101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic model of immune checkpoint inhibitors combined with anti-angiogenic agents in unresectable hepatocellular carcinoma.
    Li X; Sun W; Ding X; Li W; Chen J
    Front Immunol; 2022; 13():1060051. PubMed ID: 36532029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential predictors for survival in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: A meta-analysis.
    Xu H; Cao D; Zheng Y; Zhou D; Chen X; Lei J; Ge W; Xu X
    Int Immunopharmacol; 2021 Nov; 100():108135. PubMed ID: 34530205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Analysis Identifies Liver Metastases as Negative Predictive Factor for Immune Checkpoint Inhibitors Treatment Outcome.
    Chen XJ; Ren A; Zheng L; Zheng ED; Jiang T
    Front Immunol; 2021; 12():651086. PubMed ID: 34248939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.